Motor problems in Prader-Willi syndrome (PWS) are presumably related to abnormal body composition and certain neuromuscular abnormalities. The authors reviewed the literature to evaluate the extent to which body composition is affected and gathered all findings on neuromuscular functioning in PWS. A systematic review was conducted in four databases . The methodological quality of each included article was evaluated. Thirty-eight papers were included: body composition (9 studies), neuromuscular functioning (7) and growth hormone (GH) effect studies (23). Increased fat mass and decreased lean body mass are characteristics of PWS. As a result, muscle mass is decreased by 25-37%, which might explain partly the weakness and hypotonia. However, there are also structural and functional muscle abnormalities, and cortical motor areas are hypo-excitable in PWS patients. Moreover, disuse as result of decreased activity in PWS could also contribute. GH treatment positively influences body composition, but does not normalize it. Training could prevent disuse and improves body composition. Therefore GH treatment and training will probably enhance one another.
Introduction
Prader, Labhart, and Willi first described Prader-Willi syndrome (PWS) in 1956 (Prader et al., 1956) . PWS is a neurogenetic disorder resulting from absent expression of the paternal region of chromosome 15q11-13. In about 70% of cases it is caused by a paternal deletion (Butler et al., 1986; Ledbetter et al., 1981) , in about 25% of cases by maternal uniparental disomy (Holm et al., 1993; Mascari et al., 1992; Nicholls et al., 1989) , and in 1-5% it is caused by an imprinting center mutation or translocation (Cassidy, 1997; Saitoh et al., 1997) . The estimated prevalence is 1 in 10,000-30,000 births (Whittington et al., 2001) . PWS is characterized by a wide variety of physical, cognitive, and behavioral defects. The most significant characteristics are hypotonia in infancy, hypogonadism, obesity, short stature, motor delay, cognitive deficits, and mild dysmorphic facial features (Cassidy, 1984; Holm et al., 1993) . The presence of symptoms is mostly age-dependent; not all symptoms are expressed in all patients, and the severity of disabilities differs between patients. In this paper we are particularly interested in the symptoms in PWS which contribute to their motor problems.
Motor performance in PWS is particularly affected in infancy. In the majority of cases, newborns are severely hypotonic, inactive and sometimes almost motionless. After several weeks or months the infants become more responsive and are capable of more spontaneous movement, although they continue to suffer from hypotonia, muscle weakness and as a result severely delayed motor development (Afifi and Zellweger, 1969; Cassidy, 1984; Eiholzer et al., 2001 Eiholzer et al., , 2008 Festen et al., 2008a) . Motor problems are still present in childhood and adulthood, and decreased activity in PWS patients is reported (Butler et al., 2007; Davies and Joughin, 1993; Hill et al., 1990; Schoeller et al., 1988; Van Mil et al., 2000a) . PWS patients score well below the normal range on standardized motor performance tests (Carrel et al., 2002; Mullins and Vogl-Maier, 1987) , and they have an abnormal gait pattern (Vismara et al., 2007) . The causes of hypotonia, muscle weakness, and motor problems in PWS patients are not clear; it is presumed however that the contributing factors are the abnormal body composition in PWS patients, with an increase in fat mass and a decrease in muscle mass, and possibly some degree of neuromuscular abnormality (Lewis, 2000; Sone, 1994) .
Abnormal body composition in PWS patients is thought to be related to hormonal deficiencies as a result of hypothalamic dysfunction (Burman et al., 2001; Eiholzer and Whitman, 2004; Swaab, 1997) . Indeed several studies have found anatomical and functional abnormalities of the hypothalamus (Gabreëls et al., 1998; Iughetti et al., 2008; Miller et al., 1996; Miller et al., 2008; Swaab et al., 1995) . Moreover, growth hormone (GH) (Eiholzer et al., 2000a) and hormones of the thyroid (Butler et al., 2007; Festen et al., 2007) , gonads Muller, 1997) , and adrenal cortex (De Lind van Wijngaarden et al., 2008) are found to be affected. The most significant finding in relation to body composition in PWS patients is GH deficiency. GH deficiency presumably leads to the short stature, decreased lean body mass, increased fat mass, and decreased bone mineral density in PWS patients (Eiholzer et al., 2000a) . GH treatment leads not only to an increase in height, but also to a decrease in fat mass and an increase in lean body mass in PWS patients (Carrel et al., 1999 (Carrel et al., , 2002 Davies et al., 1998) . In some GH studies it is presumed that GH treatment could also have a positive effect on muscle strength, motor development and/or performance, because GH positively influences body composition (Carrel et al., 1999 Eiholzer et al., 1998) .
To evaluate the extent to which the body composition abnormalities in PWS may contribute to the motor problems, it is necessary to gather insight into the severity of the abnormalities in relation to age, as well as their progress over time. To our knowledge there are no longitudinal studies that focus on body composition in PWS. There are several cross-sectional studies but the results of these studies have never been systematically reviewed. We wanted to perform a systematical literature study on body composition in PWS to critically review the findings and obtain more insight into the presumed relationship between body composition abnormalities, hypotonia, muscle weakness, and motor problems in PWS. Additionally it has been hypothesized that abnormalities in neuromuscular functioning could contribute to the motor problems in PWS patients. Only three studies are frequently mentioned with regard to this hypothesis (Afifi and Zellweger, 1969; Civardi et al., 2004; Sone, 1994) . We wanted to know if there are more studies that focus on neuromuscular functioning in PWS and therefore expanded our literature study to both topics. In this paper we describe the findings of our systematic literature study regarding body composition and neuromuscular functioning in PWS and review the effects of GH treatment on body composition. The methodological quality of all references included in this review was assessed in order to evaluate the quality and authority of the reported findings.
Method

Search strategy
We identified relevant papers in a comprehensive literature search that focused on body composition and neuromuscular functioning in PWS. First of all, a search for English-language publications was conducted, covering the period from January 1956, the year in which the first description of the syndrome was published, to January 2010 and using four electronic databases: Pubmed, Embase, Cinahl, and Psycinfo. Since only Embase and Psycinfo used the same thesaurus terms and major subheadings, the searches were performed separately in each database and results were combined afterwards. The articles on body composition in PWS were found based on "body composition" as search and mesh term. The articles on neuromuscular functioning were found using the following search or mesh terms: muscle(s), musculoskeletal, neural physiological phenomena, musculoskeletal system, musculoskeletal development, and musculoskeletal physiological phenomena. The search strings are listed in Appendix A. The reference lists from relevant papers were then checked manually for supplementary articles not previously identified.
Selection criteria
Overlapping articles were deleted. Each abstract was screened by two authors (LR + MN) and included if it was related to an original scientific article focusing on either body composition or neuromuscular functioning in PWS. The article was excluded if it concerned a case report, an opinion-based article, a non-systematical review, or animal research and if there was no abstract available. Furthermore, articles were excluded if the main subject was outside the scope of our study. The exclusion criteria are presented in Table 1 . After selection the full text article was screened again based on the inclusion and exclusion criteria (Fig. 1 ).
Evaluation of the methodological quality
The methodological quality of the included references was evaluated based on technical aspects of the study design. After excluding "Case reports" and "Non-systematical reviews", we included five different study designs: Randomized Controlled Trials (RCT), Cohort Designs, Clinical Controlled Trials (CCT), Case Series (CS), and Observational Between-Subject Designs (O-BSD). Since standard checklists have not been developed for all of these designs, we therefore selected criteria from three standard checklists: Evidence-Based RichtlijnOntwikkeling (EBRO, 2005) , the Physiotherapy Evidence Database Scale (PEDro, 1999) and the Critical Appraisal Skills Programme (CASP, 2006) . We selected thirteen relevant criteria: (1) Randomization, (2) Group definition, (3) Selection bias, (4) Group comparability, (5) Treatment procedure, (6) Blinding, (7) Control period, (8) Study duration, (9) Measurement procedure, (10) Comparability of treatment, (11) Confounding effects, (12) Loss, and (13) Intention-to-treat. All 13 criteria were used to evaluate the RCT, for the CCT 12, for the Cohorts 10, for the CS 7, and for the O-BSD 6. Two authors (LR + LV) independently scored each criterion. Its quality was determined once it was established whether or not the criterion was reported. If the criterion was well described and its quality was good, two points were assigned for that criterion. One point was assigned if the criterion was incompletely described and/or its quality was doubtful. Zero points were assigned if the criterion was not described. The level of agreement between authors was determined by Cohen's Kappa. The percent- age of the maximum score was calculated in order to compare the evaluations of different designs. For example: the maximum score for an RCT was 26 points (13 × 2 points); if a study was evaluated with 18 points, it scored 69%.
Results
Results of electronic database search
The electronic search identified 287 unique references, 38 of which met our inclusion criteria. A flow chart of the selection procedure is presented in Fig. 1 . Thirty-one references were found on body composition in PWS, of which nine were solely focused on body composition and 22 on the effects of GH treatment on body composition. In total 23 GH effect studies were evaluated, since one study contained results from an RCT as well as a CS. Seven references were found on neuromuscular functioning in PWS. The body composition studies (n = 9) were all O-BSD. Six of the neuromuscular studies were O-BSD and there was one Cohort. In the GH effect studies four design types were found: RCT (n = 9), CCT (n = 1), Cohort (n = 1), and CS (n = 12).
Body composition in PWS
Study characteristics
A description of the study characteristics is presented in Table 2 . All nine body composition references were O-BSD. Body composition was compared to normal healthy individuals (n = 4) or obese individuals (n = 6). In six studies the PWS group was smaller than 20 patients and in three studies the group was larger than 20 patients.
Methodological quality
Initially the raters reached an agreement of 87% (Cohen's Kappa 0.77) with respect to all the criteria of the nine O-BSD studies (9 × 6 = 54 criteria). 100% consensus was reached following consultation. The quality scores for the articles reached 67 and 82% of the maximum score. The selection procedure of patients is not described in any of the O-BSD studies, but from the patient descriptions it is possible to evaluate whether or not the patients included are representative of PWS patients in general. Seven studies do not report whether there was patient loss. In the three studies with the lowest scores (67%), authors do not correct for possible differ- ences in height between control subjects and PWS patients, who are normally significantly shorter.
Methods used
Body composition can be measured using different techniques based on different principles and assumptions. Dual Energy X-Ray Absorptiometry (DEXA) is a scanning technique that measures the differential attenuation of two X-rays as they pass through the body. It distinguishes total Bone Mineral Content (BMC) from soft tissue and subsequently divides the latter into fat and lean tissue. Lean tissue consists mainly of muscle tissue and is called Lean Body Mass (LBM). Fat Free Mass (FFM) is the sum of LBM and BMC (Uszko-Lencer et al., 2006) . Another way of measuring body composition is based on total body water, which is called Deuterium Dilution (DD). First total body water is measured, usually with the double labeled water. Subsequently FFM is computed based on the assumption that total body water represents a fixed proportion of FFM (hydration factor of 0.73) and that fat is anhydrous. Fat mass PWS vs. Norm:
Reduced FFM is not the sole explanation for the lower energy expenditure seen in patients with PWS. 
PWS patients show a peculiar body composition, to some extent similar to that found in subjects deficient in growth hormone. H; W; BMI; SMR (respiratory chamber);
BMR and SMR are low in patients with PWS because of a low FFM. 
In PWS adiposity is probably related to abnormal GH function and physical inactivity. is calculated by subtracting the FFM from the total body weight (Uszko- Lencer et al., 2006) . Since FFM and body fat have different electrical properties it is also possible to measure body composition with Bioelectrical Impedance Analysis (BIA). In BIA two conductors are applied to the body and resistance is measured. Conductivity through FFM, which consists of water and electrolytes, is greater than through body fat. Based on the resistance, and taking into account gender, weight, and height, it is possible to calculate fat mass and FFM (Abu et al., 1988) . Both DEXA and DD are accurate methods for measuring body composition (Uszko-Lencer et al., 2006). DEXA has the advantage that it not only distinguishes fat mass and FFM, but also LBM and BMC; in addition it can define body composition in different body regions (Brambilla et al., 1997; Theodoro et al., 2006) . BIA is a less accurate technique for measuring body composition; it is generally assumed that it requires pathology-specific equations, which are not available for PWS (Uszko-Lencer et al., 2006) .
Results of body composition in PWS
The results of the nine body composition articles were added to the results of six GH studies in which PWS patients were compared to norm values before the start of GH treatment (Table 4 : 4.1, 4.2, 4.3, 4.5 and Table 5 : 5.1, 5.5). All studies report an increase in fat mass and a decrease in LBM in PWS patients compared to normal healthy individuals. This pattern is found in adults, children, and even in PWS infants who are still underweight ( Table 5 : 5.5). In both PWS infants and children LBM is 50-60% of total body mass, whereas in normal healthy individuals this is about 80% (Table 2: 2.4, and Table 4 : 4.2, 4.5). Moreover, fat distribution is different in PWS patients. Although PWS patient have the same percentage of body fat in comparison to individuals with simple obesity, the fat mass in PWS patients is significantly more increased in the limbs (Table 2 : 2.5, 2.8). In contrast, LBM is decreased in all body regions (Table 2 : 2.5, 2.8).
The marked increase in fat mass in PWS patients indicates an imbalance between energy intake and energy expenditure. This cannot be solely explained by an increased energy intake since even when PWS patients are underweight in infancy, before hyperphagia develops, body fat is increased (Table 2 : 2.1, 2.2). Even more importantly, energy expenditure is decreased in PWS infants, children and adults (Table 2 : 2.1, 2.3, 2.4, 2.6, 2.9, and Table 4: 4.5). In normal healthy adults there is a relation between body composition and energy expenditure, LBM is found to be the most predictive variable for Basal Metabolic Rate (BMR) (Cunningham, 1980) . Since BMR is responsible for 70% of total energy expenditure, LBM is the most predictive variable for energy expenditure. With respect to energy expenditure, some authors report that decreased BMR or decreased total energy expenditure can solely be explained by decreased LBM in PWS (Table 2: 2.1, 2.6), whereas others report that LBM is not solely responsible and that PWS patients are probably also less active (Table 2: 2.3, 2.4, 2.9).
Neuromuscular functioning in PWS
Study characteristics
The seven references regarding neuromuscular functioning in PWS belong to four different domains of the motor system: (1) corticospinal excitability and conductivity, (2) muscle tissue, (3) biochemical muscle characteristics, and (4) muscle functioning. A description of the study characteristics is presented in Table 3 . Six O-BSD studies were included and one Cohort. PWS patients were compared to norm values, normal control subjects, hypotonic control subjects, and/or obese control subjects. In only two studies more than 20 patients were included.
Methodological quality
Initially the raters reached an agreement of 98% (Cohen's Kappa 0.96) with respect to all the criteria of the seven articles (7 × 6 = 42 criteria). 100% consensus was reached following consultation. The quality scores for the articles reached 50-92% of the maximum score.
Methods used
The following methods were used to evaluate neuromuscular functioning in PWS: transcranial magnetic stimulation (TMS) of the motor cortex and motor evoked potential (MEP) to evaluate corticospinal excitability and conductivity (Civardi et al., 2004) ; muscle ultrasounds and muscle biopsies to evaluate muscle tissue (Heckmatt et al., 1988; Sone, 1994; Afifi and Zellweger, 1969) ; levels of CoQ10, an essential coenzyme for energy synthesis, to evaluate biochemical muscle characteristics (Butler et al., 2003) ; and maximum expiratory and aspiratory pressure and isokinetic dynamometry to assess muscle functioning of thoracic muscles and knee flexor (Hakonarson et al., 1995; Capodaglio et al., 2009 ).
Results of neuromuscular functioning in PWS
Motor cortex functioning seems to be affected in adult PWS patients. Based on TMS and MEPs the relaxed motor threshold is increased and intracortical facilitation is decreased, which indicates hypo-excitability of the motor cortical areas (Table 3: 3.1). Qualitative studies from muscle biopsies reveal some muscle tissue abnormalities: type-2 fiber atrophy, type-2B fiber deficiency and an increased amount of the immature type-2C fibers (Table 3: 3.3), morphological abnormalities of contractile elements and mitochondria (Table 3: 3.2). Additionally, type-1 fiber size is significantly decreased and variability is increased (Table 3: 3.3) . The muscle ultrasound scans were normal, echo intensity was not increased which indicates that muscle tissue is not replaced by fat or fibroses in PWS patients (Table 3: 3.4). These finding were not statistically tested. Compared to normal controls, in muscles of PWS patients CoQ10 levels are decreased, indicating possible mitochondrial dysfunction. The normal association between CoQ10 levels and age was also absent (Table 3 : 3.5). Both studies on muscle function report decreased muscle strength: compared to controls muscle force in knee flexors is 70% decreased (Table 3: 3.7), and decreased muscle strength of thoracic muscles in PWS patients leads to impaired pulmonary function (Table 3: 3.6).
Effects of GH treatment on body composition
Study characteristics
The literature search revealed 22 references pertaining to the effects of GH treatment on body composition. In total 23 GH effect studies were evaluated, since one study contained results from an RCT as well as a CS. Of the studies included nine were RCTs (40%) and of the remaining 14 studies the majority were CS. First we present the results of the RCTs, the strongest study design for evaluating treatment effects. The results of the 14 non-randomized GH effect studies are presented subsequently.
Study characteristics of the RCTs
A description of the study characteristics is presented in Table 4 . GH was compared to placebo (n = 2), or no GH treatment (no-GH, n = 5), and two studies examined the dose-dependent effect of GH treatment. The control period varied between 6 (n = 3), 12 (n = 4) and 24 (n = 2) months. In two studies sample size was smaller than 20 patients and in seven studies sample size was larger than 20 patients. Body composition was measured using DEXA, DD, or BIA (see Section 3.2.3)
Methodological quality RCTs
Initially the raters reached an agreement of 94% (Cohen's Kappa 0.89) with respect to all the criteria of the nine RCTs (9 × 13 = 117 criteria). 100% consensus was reached following consultation. The scores were between 65% and 77% of the maximum score. The selection procedure of patients is not described in any of the RCTs, but from the patient descriptions it is possible to evaluate whether or not the patients included are representative of PWS patients in general. Eight of the studies do not report whether the treatment group and control group were similar with regard to percentage of body fat and LBM before the start of treatment, although the groups were similar with respect to age and gender. None of the RCTs report an intention-to-treat, it is therefore not possible to evaluate whether everyone who received treatment was considered part of the trial, and whether they completed it or not. Since patient loss was absent or small in the RCTs, the absence of an intention-to-treat is not likely to result in misinterpretation. 
Results RCTs: effect of GH treatment on body composition
All of the studies included reported beneficial effects of GH treatment on body composition: there is a decrease in the percentage of body fat and an increase in LBM during treatment. For body fat both between-group effects (Table 4: 4.1, 4.5, 4.6, 4.9) and withingroup effects are found (Table 4 : 4.1, 4.2, 4.3, 4.4, 4.5). In children the percentage of body fat decreases by about 20% during treatment, but remains above normal (Table 4 : 4.1, 4.4, 4.5). The effect is far weaker in adults that have not been treated before, about 4% (Table 4 : 4.9). Also for LBM between-group effects (Table 4: 4.1, 4.3, 4.6) and within-group effects are reported (Table 4 : 4.1, 4.2, 4.3, 4.4, 4.9). In children LBM increases by about 25-40%, but it does not normalize (Table 4 : 4.1, 4.4, 4.5). The effect is minimal in adults that have not been treated before, about 3% (Table 4 : 4.9). Since GH causes an increase in height, LBM should be corrected for height in infants and children but this was only done in one study. LBM corrected for height did not increase, but since it decreased in the control group a between-group difference was found (Table 4: 4.3). The dose-dependent effect studies of GH treatment demonstrate that a dose of >0.3 mg/m 2 /day is necessary to keep the percentage of body fat below baseline levels and LBM above baseline levels (Table 4 : 4.7, 4.8).
Furthermore, small effects of GH treatment on motor performance and energy expenditure have been found. A between-group difference regarding motor development in infants is reported after 6 months of GH treatment. However after 12 months this effect remains only significant in patients who received GH treatment before 18 months of life (Table 4 : 4.1). In children physical strength and agility improved (4.5) and expiratory muscle strength improved (Table 4 : 4.5, 4.6). Also in infants and children energy expenditure increased compared to the control group (Table 4: 4.1, 4.2, 4.6).
Study characteristics of the non-RCTs
A description of the study characteristics is presented in Table 5 . One CCT, one Cohort, and 12 CS were included. In the CCT GH was compared to CoQ10 supplementation, and in the Cohort GH was compared to no-GH treatment. In the CS body composition in patients was measured at baseline and after a particular time of treatment. The treatment duration differed between studies from 
77%
Population: m = mean age and age range, PWS-GH = PWS GH treatment group, PWS-no-GH = PWS control group, O-control = obese control group. Anthropometric measurements: H = height, W = weight, GR = growth rate, BMC = bone mineral content, BMI = body mass index, Head-C = head circumference, Arm-C = arm circumference, Waist-C = waist circumference, Hip-C = hip circumference. Body composition measurements: FM = fat mass, BF% = body fat percentage, FFM = fat free mass, LBM = lean body mass, LBM-age = lean body mass corrected for age, LBM-height = lean body mass corrected for height. Energy measurements: TEE = total energy expenditure, REE = resting energy expenditure. Measurement methods: DD = Deuterium Dilution, DEXA = dual energy X-ray absorptiometry, IC = Indirect Calorimetry, BIA = Bioelectrical Impedance Analysis. Effect indication: = = similar, ↑ = increased, ↓ = decreased. T.6months vs. T.0:
GH has a positive effect on body composition in patients with PWS. 
86%
Design: CCT = Clinical Controlled Trial, CS = Case Series. Population: m = mean age and age range, PWS-GH = PWS GH treatment group, PWS-Q10 = PWS CoQ10 treatment group, PWS-no-GH = PWS control group. Anthropometric measurements: H = height, W = weight, GR = growth rate, BMC = bone mineral content, BMI = body mass index, Head-C = head circumference, Arm-C = arm circumference, Waist-C = waist circumference, Hip-C = hip circumference. Body composition measurements: FM = fat mass, BF% = body fat percentage, BF%-Limbs = body fat percentage of limbs, BF%-trunk = body fat percentage of trunk, BF%-age = body fat percentage corrected for age, FFM = fat free mass, LBM = lean body mass, LBM-age = lean body mass corrected for age, LBM-height = lean body mass corrected for height. Energy measurements: REE = resting energy expenditure. Measurement methods: DD = Deuterium Dilution, DEXA = dual energy X-ray absorptiometry, IC = Indirect Calorimetry. Effect indication: = = similar, ↑ = increased, ↓ = decreased.
0.5 to 7 years: 0.5 year (n = 2), 1 year (n = 4), 2 years (n = 2) and more than 3 years (n = 4). In only two longer study, patients were measured repeatedly during treatment (Table 5: 5.7, 5.9) . In nine studies sample size was smaller than 20 patients and in five studies the sample size was larger than 20 patients. Body composition was measured using DEXA or DD (see Section 3.2.3).
Methodological quality non-RCTs
Initially the raters reached an agreement of 98% (Cohen's Kappa 0.96) with respect to all the criteria of the 14 non-RCTs ((13 × 7) + (1 × 9) + (1 × 11) = 104). 100% consensus was reached following consultation. The quality scores for the articles reached 64% and 86% of the maximum score. The selection procedure of patients is not described in 12 non-RCTs, but from the patient descriptions it is possible to evaluate whether or not the patients included are representative of PWS patients in general.
3.4.7. Results non-RCTs: effect of GH treatment on body composition
All authors report positive effects for GH treatment on percentage of body fat and on LBM and therefore support the findings of the RCTs. An effect on body composition compared to baseline is still seen after five years of GH treatment (Table 5: 5.5, 5.13) . In two studies the effects of GH were evaluated repeatedly during several years of treatment. It was found that treatment effects on body composition stabilized after the first year (Table 5: 5.7, 5.9) . LBM was corrected for height in only two studies with children. Heightcorrected LBM increased in infants (Table 5 : 5.1) but not in children (Table 5 : 5.9). In one study SDS for percentage of body fat and LBM were used, percentage of body fat decreased and LBM remained stable (Table 5 : 5.7). Effects of GH treatment on motor performance are also reported: physical strength and agility increased and expiratory muscle strength improved in children (Table 5 : 5.8). Moreover, non-significant effects of GH on motor performance were reported. Infants who were treated with GH spoke their first words and walked earlier than is usually seen in PWS (Table 5: 5.2). Parents of children treated with GH reported increased physical activity and performance in their children after starting GH treatment (Table 5: 5.6).
Discussion
Principal findings
Study characteristics
The sample size of the included studies was relatively small, probably due to the low incidence of the syndrome. This is presumably also the reason why the age range was sometimes quite large, and control and follow-up periods were relatively short. The studies on body composition and GH treatment were methodologically well performed and although overlapping outcome variables were used, measurement techniques and age bands differed, and therefore a meta-analysis was not possible. It would be recommendable to determine a standard method for evaluating body composition in PWS patients so that it is possible to perform meta-analysis. The quality of the studies on neuromuscular functioning varied from good to moderate. Since they focused on very different aspects of neuromuscular functioning, there was no overlap in outcome variables.
Body composition in PWS
The first goal of this literature study was to gather insight into the severity of body composition abnormalities in PWS, its relation to age, and its progress over time. Our study revealed nine methodologically well-performed cross-sectional O-BSD reports on body composition in PWS. The reported findings were consistent: PWS patients have increased fat mass and decreased LBM. This pattern is characteristic of the syndrome, since it was found in adults (Brambilla et al., 1997; Schoeller et al., 1988; Theodoro et al., 2006; Van Mil et al., 2000b; Van Mil et al., 2001) , children (Brambilla et al., 1997; Eiholzer et al., 1999; Hill et al., 1990; Schoeller et al., 1988; Theodoro et al., 2006; Van Mil et al., 2000b , 2001 ) and even in PWS infants that are still underweight (Bekx et al., 2003; Carrel et al., 2004; Sone, 1994; Whitman et al., 2004) . Insight into the severity of the abnormalities in relation to age and its progress over time should ideally be supported by longitudinal studies. We found only cross-sectional reports, which indicate that the relationship between fat mass and LBM becomes more out of balance over time. Two phenomena appear to be responsible for this. First, in normal children body fat percentage is high in infancy and decreases over time in childhood (Butte et al., 2000; Van der Sluis et al., 2002) in contrast, in PWS children body fat is already increased in infancy, and increases further in childhood. Over time this results in more than double the amount of body fat in children and adults with PWS in comparison to normal individuals. Second, in normal obesity LBM increases proportionally to the increase in fat mass (Forbes, 1997; Forbes and Welle, 1983) , in PWS patients LBM does not increase when fat mass increases. Several studies reported that LBM is only 50-60% of the total body mass in PWS patients instead of 80%, this is 20-30% lower (Carrel et al., 1999 Van Mil et al., 2000a) . Since LBM consists mainly of muscle mass, it can be concluded that muscle mass is decreased by 25-37% in PWS patients ((20/80) × 100% = 25%, (30/80) × 100% = 37%). This presumably affects muscles in all body regions, since LBM is decreased in all body regions (Brambilla et al., 1997; Theodoro et al., 2006) , and it is assumable that muscle strength is affected. Longitudinal studies on body composition are necessary to confirm these cross-sectional findings.
Neuromuscular functioning in PWS
The second goal of this literature study was to systematically gather studies on neuromuscular functioning in PWS. We only found seven explorative studies focusing on quite distinct subjects. Most studies reported structural and functional muscle abnormalities: morphological abnormalities of contractile elements and mitochondria (Afifi and Zellweger, 1969) , type-2 muscle fiber atrophy, with type-2B fiber deficiency and increased immature type-2C muscle fibers (Sone, 1994) decreased type-1 muscle fiber size (Sone, 1994.) , decreased CoQ10 levels in muscle tissue indicating abnormal mitochondrial function (Butler et al., 2003) , and decreased strength of thoracic muscles and knee flexor (Capodaglio et al., 2009; Hakonarson et al., 1995) . Only one study reported hypoexcitability of the cortical motor areas (Civardi et al., 2004) . Based on these preliminary results, it can be hypothesized that the clinical symptoms originate at least partly from innate cortical and/or muscle pathology and partly from a secondary phenomenon of disuse. Therefore more research is necessary to study the relationship between the clinical symptoms, hypotonia and decreased muscle mass and strength, and the presence of structural and functional abnormalities in muscles and motor cortex.
Effects of GH treatment on body composition
The third goal of this literature study was to evaluate the reported effects of GH treatment on body composition in PWS patients. Our study revealed 9 methodologically well-performed RCTs and 14 methodologically well-performed non-RCTs. The reported findings were mainly consistent: GH positively influences body composition; it decreases fat mass and increases LBM. Nevertheless some critical remarks must be made. First, in children the effect of GH on body fat is much larger (20%) (Carrel et al., 1999; Lindgren et al., 1998; Whitman et al., 2004) , than in adults (4%) (Höybye et al., 2003) , however, even in children, body fat percentage does not normalize. Second, although for all studies the effect of GH on LBM is reported to be much larger in children than in adults, the actual effect seems to be overestimated because LBM is usually not corrected for height, despite GH causing an increase in growth rate. In three out of four studies in which LBM was corrected no increase was found (de Lind van Wijngaarden et al., 2009; Eiholzer et al., 2000b; Festen et al., 2008b) . Third, after the first treatment year there is no additional effect of GH on body composition (Eiholzer et al., 2000b) , but the initial effect on body fat and LBM remains stable over time (Höybye, 2007; Lindgren and Lindberg, 2008) . Therefore, GH seems to prevent LBM and body composition becoming more out of balance over time, a phenomenon normally seen in PWS. Furthermore, GH deficiency in PWS is probably not the only cause of body composition abnormalities, since GH treatment completely normalizes length but does not normalize body composition (Lindgren and Lindberg, 2008) . More research is necessary to further evaluate the long-term effects of GH treatment on body composition and the presumed effect on muscle mass.
This article in relation to the literature
This is the first systematic review on body composition and neuromuscular functioning in PWS. In fact, to our knowledge, there is only one other systematic review on autism in PWS (Veltman et al., 2005) . Comparison can be made to some non-systematic reviews on body composition and GH treatment in PWS Burman et al., 2001; Carrel and Allen, 2003) . In general their findings are in line with ours but they do not provide insights into the severity of body composition abnormalities, its relation to age, its progress over time, and the implications of correcting LBM for height. We found one opinion based review in which it is proposed, that decreased muscle strength could be the result of abnormal protein synthesis in muscle tissue as result of decreased GH secretion (Lewis, 2000) . In our systematic literature no evidence was found for this suggestion.
Understanding motor problems in PWS
We performed this review to answer the question to which extent abnormal body composition and abnormal neuromuscular functioning may contribute to the motor problems in PWS. We found evidence that muscle mass is decreased by about 25-37%. It is suggested that this decrease is related to GH deficiency in PWS (Burman et al., 2001; Eiholzer and Whitman, 2004; Swaab, 1997) . However, also structural and functional abnormalities in muscles are found (Afifi and Zellweger, 1969; Butler et al., 2003; Capodaglio et al., 2009; Hakonarson et al., 1995; Sone, 1994) . Although there is a rough linear relationship between muscle strength and muscle cross-sectional area (Ikai and Fukunaga, 1968) , in our opinion, decreased muscle mass cannot be the only reason for decreased muscle strength in PWS patients. For example, Capodaglio et al. (2009) reported that muscle strength in the knee flexor was 70% lower than normal and therefore much more affected than expected based on decreased muscle mass alone. Inactivity may also contribute to both decreased muscle mass and muscle strength, since PWS infants are found to be less active even before birth (Whittington et al., 2008) . This inactivity may also negatively influence motor performance and development of cortical motor areas and the neuromuscular systems (Changeux, 1997; Hadders-Algra, 2001; Hadders-Algra, 2004; Purves and Lichtman, 1980) . Another aspect that could contribute to motor problems in PWS is the fact that although PWS patients need more muscle strength in daily activities, because of their overtime increasing BMI, the ratio between LBM and fat mass decreases overtime. In the literature there is a strong focus on body composition abnormalities as result of GH deficiency in PWS as cause of the motor problems. Indeed they do contribute to it, but cannot totally explain them. Research in PWS should therefore focus on other possible causal factors. Another interesting finding in this respect is that in PWS motor performance is found to improve over time although body composition becomes more out of balance over time. Motor problems are most striking in infancy, in which motor development is dramatically constraint by severe hypotonia and muscle weakness, with as result that infants are almost motionless, because they cannot overcome gravity (Afifi and Zellweger, 1969; Cassidy, 1984; Eiholzer et al., 2008) . Especially in this period of life motor activity is a strong stimulator for cortical and muscular development, the so called sensitive period (Changeux, 1997; Hadders-Algra, 2001 , 2004 Purves and Lichtman, 1980) . In our opinion it is very likely that motor problems in PWS are also related to innate central nervous system defects, in the same manner as endocrine abnormalities are related to defects of the hypothalamus (Burman et al., 2001; Eiholzer and Whitman, 2004; Swaab, 1997) . Indeed, there are some structural brain abnormalities found in PWS patients (Gabreëls et al., 1998; Iughetti et al., 2008; Kim et al., 2006; Miller et al., 1996 Miller et al., , 2008 Swaab et al., 1995; Yamada et al., 2006) , but only one study reports a possible relationship between brain abnormalities and hypotonia (Yamada et al., 2006) . The hypoexcitability of cortical motor areas in PWS patients are hypothesized as of neurogenetic origin (Civardi et al., 2004) , although these findings can also be related to disuse and problematic development.
Due to the strong dominant focus on body composition as contributing factor, and the beneficial results from GH on body composition, it is thought that GH treatment could also positively affect muscle strength and motor performance (Carrel et al., 1999 Eiholzer et al., 1998) . Although beneficial effects of GH treatment on motor performance have been reported (Carrel et al., 1999 Myers et al., 2000; Whitman et al., 2004) , it is questionable whether there is a direct relationship between GH treatment, muscle mass, muscle strength and motor performance. We are of the opinion that patients will benefit more from GH treatment when also participating in a training program, since it has been shown that also training has a positive effect on body composition in PWS patients (Eiholzer et al., 2003; Schlumpf et al., 2006; Silverthorn and Hornak, 1993) and training prevents disuse. Since GH treatment alone does not normalize body composition it is possible that GH treatment and training enhance one another and the combination of the two will lead to better results for both body composition and motor performance. Moreover, we advocate that especially young infants can profit from early intervention focusing on skill acquisition and strength training to increase motor development, because in the sensitive period the effect of training influences cortical and muscular development most (Changeux, 1997; Hadders-Algra, 2001 , 2004 Purves and Lichtman, 1980) . To get more insight in the relationship between the clinical signs and symptoms and the structural and functional impairments, training and the effect of training on muscle strength, muscle tissue and cortical motor areas should be monitored not only with clinical relevant outcome measurements, but also with measurements focusing on structural and functional changes in muscles and cortex using non-invasive muscle ultrasound scans Pillen et al., 2003) and functional MRI.
General conclusions
In conclusion, the research on body composition and the effect of GH has brought a lot of benefits for patients with PWS in managing the imbalance between fat mass and LBM, which in general has a positive effect on motor performance and fitness. However, insight in the origin of severe motor problems and hypotonia in infancy, and decreased muscle mass and strength in children, adolescents, and adults with PWS is poor at this moment. We found some preliminary findings that decreased muscle mass, hypothonia, muscle weakness and motor problems in PWS are related to impairments in the nervous and muscular system. Especially the combination of mental retardation and psychiatric disorders, both characteristic for PWS, point into the direction of brain pathology. Research focused on functional and structural abnormalities of cortical motor areas in PWS patients is therefore needed. It seems also that the abnormalities in muscle mass and strength are related to structural and/or functional abnormalities in muscles. However, the interaction between (dis)use and the more structural and functional abnormalities seems to be a clinical relevant finding, since it has been shown that training also has a positive effect. Future research should be focused on getting insight in the relationship between clinical signs and symptoms, and the structural and functional abnormalities in the motor system.
